Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2504813 | 0.98 | KMT2A (0.46) | KMT2ANPC1RAB9AMEN1MAPT | |
| Hydrochloric Acid SCHEMBL7406469 | 0.83 | GAA (0.41) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL4352976 | 0.80 | GAA (0.42) | KMT2ANPC1RAB9AMEN1MAPT | |
| Hydrochloric Acid SCHEMBL407377 | 0.79 | POLB (0.47) | KMT2ANPC1RAB9AMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL952830 | 0.79 | SOS1 (0.46) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL8311810 | 0.77 | KMT2A (0.47) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL824198 | 0.77 | POLB (0.48) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL29418001 | 0.77 | POLB (0.48) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL1143594 | 0.77 | SOS1 (0.47) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL22593417 | 0.76 | KMT2A (0.50) | KMT2ANPC1RAB9AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067411-A1 | NEK7 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-116332859-B | Hydrazone compound and preparation method and application thereof | 华中师范大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-116332859-A | Hydrazone compound and preparation method and application thereof | 华中师范大学 | 2023-06-27 | — | — | CN | disclosed |
| US-9169260-B2 | Amidopyrazole inhibitors of interleukin receptor-associated kinases | MERCK SHARP & DOHME CORP. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140194404-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | MERCK SHARP & DOHME LLC | 2014-07-10 | — | — | US | disclosed |
| EP-2688872-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | Merck Sharp & Dohme Corp. (US) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012129258-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | MERCK SHARP & DOHME CORP. (US) | 2012-09-27 | — | — | WO | disclosed |
| EP-1377289-A4 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | JB CHEMICALS & PHARMACEUTICALS (IN) | 2008-09-10 | — | — | EP | disclosed |
| EP-1377289-A2 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | J.B. Chemicals & Pharmaceuticals Ltd. (IN) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002074235-A2 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | J.B. CHEMICALS & PHARMACEUTICALS LTD (IN) | 2002-09-26 | — | — | WO | disclosed |
| US-5538981-A | 5-HYDROXYTRYPTAMINE RECEPTOR ANTAGONIST ACTIVITY | ELI LILLY AND COMPANY (US) | 1996-07-23 | — | — | US | disclosed |
| US-5508284-A | TREATING 5-HYDROXYTRYPTAMINE MODULATION | ELI LILLY AND COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| US-5500431-A | ANTISEROTONINE AGENTS; SEXUAL AND EATING DISORDERS | ELI LILLY AND COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| US-5488053-A | Tetrahydro-pyrido-indole | ELI LILLY AND COMPANY (US) | 1996-01-30 | — | — | US | disclosed |
| WO-1995024200-A1 | METHOD FOR TREATING 5HT2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1994024132-A1 | TETRAHYDRO-PYRIDO-INDOLE | ELI LILLY AND COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
| WO-1994023720-A1 | TETRAHYDRO-BETA-CARBOLINES | ELI LILLY AND COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0620223-A2 | Tetrahydro-pyrido-indole | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| EP-0620222-A2 | Tetrahydro-beta-carbolines | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| US-5300645-A | Condensation of cycloalkyl-, phenyl- or naphthylpyrrole ethylamines with a 2-oxazolidinone to get antiserotonine agent | ELI LILLY AND COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194404-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | IRAK4, IRAK3, IRAK1 | HDAC1 681/4885HDAC6 1359/4885KMT2A 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.